News & Media - BillionToOne

Media Coverage

November 6, 2025

MapLight Therapeutics defies government shutdown with IPO that raises more than $250 million

Learn More

Media Coverage

October 26, 2025

MapLight Therapeutics defies government shutdown with IPO that raises more than $250 million

Learn More

Media Coverage

October 17, 2025

BillionToOne's Path to a $2B+ Valuation: Strategic IPO Positioning in a High-Growth Market

Learn More

Media Coverage

October 17, 2025

BillionToOne's Path to a $2B+ Valuation: Strategic IPO Positioning in a High-Growth Market

Learn More

Media Coverage

October 17, 2025

BillionToOne targets over $2 billion valuation in US IPO

Learn More

Media Coverage

October 17, 2025

BillionToOne targets over $2 billion valuation in US IPO

Learn More

Press Releases

October 10, 2025

New Study Showed Unnecessary Burden From Continued Monitoring of Alloimmunized Pregnancies With Antigen-Negative Fetuses

Learn More

Press Releases

October 10, 2025

New Study Showed Unnecessary Burden From Continued Monitoring of Alloimmunized Pregnancies With Antigen-Negative Fetuses

Learn More

BillionToOne shares spike on first day of trading

BillionToOne shares spike on first day of trading

BillionToOne Announces Pricing of Upsized Initial Public Offering

BillionToOne Announces Pricing of Upsized Initial Public Offering

BillionToOne Announces Launch of Initial Public Offering Roadshow

BillionToOne Announces Launch of Initial Public Offering Roadshow

BillionToOne targeting around $211M in IPO

BillionToOne targeting around $211M in IPO

MapLight Therapeutics defies government shutdown with IPO that raises more than $250 million

MapLight Therapeutics defies government shutdown with IPO that raises more than $250 million

BillionToOne's Path to a $2B+ Valuation: Strategic IPO Positioning in a High-Growth Market

BillionToOne's Path to a $2B+ Valuation: Strategic IPO Positioning in a High-Growth Market

BillionToOne targets over $2 billion valuation in US IPO

BillionToOne targets over $2 billion valuation in US IPO

New Study Showed Unnecessary Burden From Continued Monitoring of Alloimmunized Pregnancies With Antigen-Negative Fetuses

New Study Showed Unnecessary Burden From Continued Monitoring of Alloimmunized Pregnancies With Antigen-Negative Fetuses

Social Posts